NIPENT

This brand name is authorized in Spain, France, Ireland, Malta, United Kingdom, United States

Active ingredients

The drug NIPENT contains one active pharmaceutical ingredient (API):

1 Pentostatin UNII 395575MZO7 - PENTOSTATIN

Pentostatin is a potent transition state inhibitor of the enzyme adenosine deaminase. The greatest activity of ADA is found in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin has been shown to have activity against a variety of lymphoid malignancies, but is most active against indolent cancers with lower ADA concentration, such as hairy cell leukaemia. Read about Pentostatin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NIPENT Powder for solution for injection/infusion	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX08	Pentostatin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 59993
Country: FR	Base de données publique des médicaments	Identifier(s): 67322542
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 46350
Country: MT	Medicines Authority	Identifier(s): AA505/04502
Country: US	FDA, National Drug Code	Identifier(s): 0409-0801